The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

paraxanthine     1,7-dimethyl-3H-purine-2,6- dione

Synonyms: p-Xanthine, Lopac-D-5385, CHEMBL1158, PubChem23157, SureCN232702, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of p-Xanthine


Psychiatry related information on p-Xanthine


High impact information on p-Xanthine


Chemical compound and disease context of p-Xanthine


Biological context of p-Xanthine


Anatomical context of p-Xanthine


Associations of p-Xanthine with other chemical compounds


Gene context of p-Xanthine


Analytical, diagnostic and therapeutic context of p-Xanthine


  1. Maternal serum paraxanthine, a caffeine metabolite, and the risk of spontaneous abortion. Klebanoff, M.A., Levine, R.J., DerSimonian, R., Clemens, J.D., Wilkins, D.G. N. Engl. J. Med. (1999) [Pubmed]
  2. The effect of liver disease on urine caffeine metabolite ratios. Denaro, C.P., Wilson, M., Jacob, P., Benowitz, N.L. Clin. Pharmacol. Ther. (1996) [Pubmed]
  3. Caffeine metabolites in umbilical cord blood, cytochrome P-450 1A2 activity, and intrauterine growth restriction. Grosso, L.M., Triche, E.W., Belanger, K., Benowitz, N.L., Holford, T.R., Bracken, M.B. Am. J. Epidemiol. (2006) [Pubmed]
  4. Methylxanthines: toxicity to humans. 3. Theobromine, paraxanthine and the combined effects of methylxanthines. Stavric, B. Food Chem. Toxicol. (1988) [Pubmed]
  5. The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. Akinyinka, O.O., Sowunmi, A., Honeywell, R., Renwick, A.G. Eur. J. Clin. Pharmacol. (2000) [Pubmed]
  6. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Faber, M.S., Fuhr, U. Clin. Pharmacol. Ther. (2004) [Pubmed]
  7. Postsynaptic dopamine/adenosine interaction: II. Postsynaptic dopamine agonism and adenosine antagonism of methylxanthines in short-term reserpinized mice. Ferré, S., Herrera-Marschitz, M., Grabowska-Andén, M., Casas, M., Ungerstedt, U., Andén, N.E. Eur. J. Pharmacol. (1991) [Pubmed]
  8. Immunomodulatory effects of caffeine: friend or foe? Horrigan, L.A., Kelly, J.P., Connor, T.J. Pharmacol. Ther. (2006) [Pubmed]
  9. Sympathomimetic effects of paraxanthine and caffeine in humans. Benowitz, N.L., Jacob, P., Mayan, H., Denaro, C. Clin. Pharmacol. Ther. (1995) [Pubmed]
  10. Caffeine disposition after oral doses. Bonati, M., Latini, R., Galletti, F., Young, J.F., Tognoni, G., Garattini, S. Clin. Pharmacol. Ther. (1982) [Pubmed]
  11. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Rostami-Hodjegan, A., Nurminen, S., Jackson, P.R., Tucker, G.T. Pharmacogenetics (1996) [Pubmed]
  12. Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors. Müller, C.E., Shi, D., Manning, M., Daly, J.W. J. Med. Chem. (1993) [Pubmed]
  13. Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. Labedzki, A., Buters, J., Jabrane, W., Fuhr, U. Biochem. Pharmacol. (2002) [Pubmed]
  14. Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities. McQuilkin, S.H., Nierenberg, D.W., Bresnick, E. Cancer Epidemiol. Biomarkers Prev. (1995) [Pubmed]
  15. Disposition of caffeine and its metabolites in man. Tang-Liu, D.D., Williams, R.L., Riegelman, S. J. Pharmacol. Exp. Ther. (1983) [Pubmed]
  16. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations. Geraets, L., Moonen, H.J., Wouters, E.F., Bast, A., Hageman, G.J. Biochem. Pharmacol. (2006) [Pubmed]
  17. Paraxanthine, a caffeine metabolite, dose dependently increases [Ca(2+)](i) in skeletal muscle. Hawke, T.J., Allen, D.G., Lindinger, M.I. J. Appl. Physiol. (2000) [Pubmed]
  18. Paraxanthine displaces the binding of [3H]SCH 23390 from rat striatal membranes. Ferré, S., Guix, T., Sallés, J., Badia, A., Parra, P., Jané, F., Herrera-Marschitz, M., Ungerstedt, U., Casas, M. Eur. J. Pharmacol. (1990) [Pubmed]
  19. Override of the radiation-induced mitotic block in human tumour cells by methylxanthines and its relationship to the potentiation of cytotoxicity. Musk, S.R., Steel, G.G. Int. J. Radiat. Biol. (1990) [Pubmed]
  20. Four-week treatment with omeprazole increases the metabolism of caffeine. Nousbaum, J.B., Berthou, F., Carlhant, D., Riche, C., Robaszkiewicz, M., Gouerou, H. Am. J. Gastroenterol. (1994) [Pubmed]
  21. Determination of theophylline in serum and saliva in the presence of caffeine and its metabolites. Moncrieff, J. J. Chromatogr. (1991) [Pubmed]
  22. Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Sachse, C., Brockmöller, J., Bauer, S., Roots, I. British journal of clinical pharmacology. (1999) [Pubmed]
  23. In vivo effect of clarithromycin on multiple cytochrome P450s. Bruce, M.A., Hall, S.D., Haehner-Daniels, B.D., Gorski, J.C. Drug Metab. Dispos. (2001) [Pubmed]
  24. Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C. Becquemont, L., Chazouilleres, O., Serfaty, L., Poirier, J.M., Broly, F., Jaillon, P., Poupon, R., Funck-Brentano, C. Clin. Pharmacol. Ther. (2002) [Pubmed]
  25. CYP2A6 activity determined by caffeine phenotyping: association with colorectal cancer risk. Nowell, S., Sweeney, C., Hammons, G., Kadlubar, F.F., Lang, N.P. Cancer Epidemiol. Biomarkers Prev. (2002) [Pubmed]
  26. Detection of quantitative trait loci affecting caffeine metabolism by interval mapping in a genome-wide scan of C3H/HeJ x APN F(2) mice. Casley, W.L., Menzies, J.A., Whitehouse, L.W., Moon, T.W. Drug Metab. Dispos. (1999) [Pubmed]
  27. Caffeine, estradiol, and progesterone interact with human CYP1A1 and CYP1A2. Evidence from cDNA-directed expression in Saccharomyces cerevisiae. Eugster, H.P., Probst, M., Würgler, F.E., Sengstag, C. Drug Metab. Dispos. (1993) [Pubmed]
  28. Orientation of caffeine within the active site of human cytochrome P450 1A2 based on NMR longitudinal (T1) relaxation measurements. Regal, K.A., Nelson, S.D. Arch. Biochem. Biophys. (2000) [Pubmed]
  29. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Fuhr, U., Rost, K.L. Pharmacogenetics (1994) [Pubmed]
  30. Evaluation of chromatographic and kit immunoassay techniques for the measurement of theophylline in serum: a study based on external quality assurance measurements. Wilson, J.F., Williams, J., Tsanaclis, L.M., Tedstone, J.E., Richens, A. Therapeutic drug monitoring. (1988) [Pubmed]
  31. K+ transport in resting rat hind-limb skeletal muscle in response to paraxanthine, a caffeine metabolite. Hawke, T.J., Willmets, R.G., Lindinger, M.I. Can. J. Physiol. Pharmacol. (1999) [Pubmed]
  32. Caffeine and its dimethylxanthine metabolites in two cases of caffeine overdose: a cause of falsely elevated theophylline concentrations in serum. Fligner, C.L., Opheim, K.E. Journal of analytical toxicology. (1988) [Pubmed]
  33. Development of a biosensor for caffeine. Babu, V.R., Patra, S., Karanth, N.G., Kumar, M.A., Thakur, M.S. Anal. Chim. Acta (2007) [Pubmed]
WikiGenes - Universities